Teva Pharma Gets a Buy Rating from Citigroup


In a report released today, Liav Abraham from Citigroup maintained a Buy rating on Teva Pharma (NYSE: TEVA), with a price target of $25. The company’s shares closed yesterday at $21.65.

According to TipRanks.com, Abraham is a 3-star analyst with an average return of 7.2% and a 48.3% success rate. Abraham covers the Healthcare sector, focusing on stocks such as Alkermes, Allergan, and Zoetis.

Teva Pharma has an analyst consensus of Hold, with a price target consensus of $20.56.

See today’s analyst top recommended stocks >>

Based on Teva Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $1.14 billion. In comparison, last year the company had a net profit of $665 million.

Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company, which engages in development, production and marketing of drugs, generic drugs, over-the-counter drugs, active ingredients for the pharmaceutical industry (APIs) and therapeutic products. It operates through two segments: Generic Medicines and Specialty Medicines.

Read More on TEVA:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts